Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
Jaeger U. et al, (2017), ONCOLOGY RESEARCH AND TREATMENT, 40, 13 - +
Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
Olszanski AJ. et al, (2017), ANNALS OF ONCOLOGY, 28
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
Garcia-Corbacho J. et al, (2017), ANNALS OF ONCOLOGY, 28
Single cell analysis of normal and leukemic hematopoiesis.
Povinelli BJ. et al, (2017), Molecular aspects of medicine
Staging gastric cancer with F-18-FDG PET-CT identifies frequent unsuspected metastases and patients at high risk of incurable disease, early recurrence and death
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 6 - 6
Validation of metabolic nodal response and a simple risk score to predict early recurrence and death after surgery for oesophageal cancer
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 56 - 57
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 1660 - 1660
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
Mead AJ. et al, (2017), The Journal of experimental medicine, 214, 2005 - 2021
COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS
Louka E. et al, (2017), HAEMATOLOGICA, 102, 265 - 265
COMPARISONS OF PATIENT MANAGEMENT IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 813 - 814
COMPARISONS OF SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 815 - 816
DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO
Goswami P. et al, (2017), HAEMATOLOGICA, 102, 602 - 602
DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM
Norfo R. et al, (2017), HAEMATOLOGICA, 102, 149 - 150
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
Hiddemann W. et al, (2017), HAEMATOLOGICA, 102, 314 - 314
RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR
O'Byrne S. et al, (2017), HAEMATOLOGICA, 102, 80 - 80
Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2017), Target Oncol, 12
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
Giustacchini A. et al, (2017), Nat Med, 23, 692 - 702
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.
Corrie P. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Chen RW. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35